- Conditions
- Non-Valvular Atrial Fibrillation, Left Atrial Appendage Closure
- Interventions
- Edoxaban, WATCHMAN LAA Closure, Aspirin and Clopidogrel, Aspirin and Warfarin
- Drug · Device
- Lead sponsor
- Scripps Health
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2019
- U.S. locations
- 1
- States / cities
- La Jolla, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–7
of 7
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Coronary Artery Disease
- Interventions
- Edoxaban 60 mg, Edoxaban 30 mg, Clopidogrel 75 mg, Aspirin 81 mg
- Drug
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Jacksonville, Florida
- Conditions
- Intracranial Hemorrhages, Atrial Fibrillation
- Interventions
- Edoxaban, Non-anticoagulant medical therapy
- Drug · Other
- Lead sponsor
- Population Health Research Institute
- Other
- Eligibility
- 45 Years and older
- Enrollment
- 948 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 10
- States / cities
- Elk Grove Village, Illinois • Lisle, Illinois • New Orleans, Louisiana + 7 more
- Conditions
- Bleeding
- Interventions
- 60mg edoxaban, 180mg edoxaban, 50 IU/kg Beriplex P/N, 25 IU/kg Beriplex P/N, 10 IU/kg Beriplex P/N
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years to 45 Years
- Enrollment
- 110 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2013 – 2014
- U.S. locations
- 1
- States / cities
- Overland Park, Kansas
- Conditions
- Arthroplasty, Replacement, Hip, Thrombosis
- Interventions
- DU-176b
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 606 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005
- U.S. locations
- 1
- States / cities
- Decatur, Georgia
- Conditions
- Atrial Fibrillation, Thromboembolism
- Interventions
- Edoxaban (DU-176b), warfarin
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 1,146 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2008
- U.S. locations
- 22
- States / cities
- Huntsville, Alabama • Anaheim, California • Beverly Hills, California + 19 more
- Conditions
- Stroke, Atrial Fibrillation, Embolism
- Interventions
- warfarin tablets, Edoxaban tablets (high dose regimen-60mg), Edoxaban tablets (low dose regimen-30mg), placebo warfarin, placebo edoxaban
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 21 Years and older
- Enrollment
- 21,105 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 316
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Gilbert, Arizona + 308 more